{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:35:09Z","timestamp":1789929309129,"version":"4.0.1"},"reference-count":151,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2017,11,2]]},"DOI":"10.1080\/13696998.2017.1363050","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T11:18:09Z","timestamp":1501586289000},"page":"1187-1199","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-2533","authenticated-orcid":false,"given":"Thomas R.","family":"Einarson","sequence":"first","affiliation":[{"name":",","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-3961","authenticated-orcid":false,"given":"Basil G.","family":"Bereza","sequence":"additional","affiliation":[{"name":",","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3257-9729","authenticated-orcid":false,"given":"Fadi","family":"Tedouri","sequence":"additional","affiliation":[{"name":"Janssen Janssen Pharmaceutica NV, Beerse, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-9871","authenticated-orcid":false,"given":"Kristel","family":"Van Impe","sequence":"additional","affiliation":[{"name":"Janssen-Cilag BV, Tilburg, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-2091","authenticated-orcid":false,"given":"Tom R.","family":"Denee","sequence":"additional","affiliation":[{"name":"Janssen-Cilag BV, Tilburg, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-8762","authenticated-orcid":false,"given":"Pieter J. T.","family":"Dries","sequence":"additional","affiliation":[{"name":"Bavo Europoort, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116820"},{"key":"e_1_3_2_3_1","unstructured":"Geohive. http:\/\/www.geohive.com\/. [Last accessed 16 January 2016]"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.565"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-010-0312-1"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00380-8"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001270050097"},{"key":"e_1_3_2_8_1","first-page":"141","article-title":"Costs of schizophrenia in The Netherlands. Schizophr","volume":"21","author":"Evers SM","year":"1995","unstructured":"Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995;21:141-53","journal-title":"Bull"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10159.x"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3182011b7f"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.3.243"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.09.001"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-013-0660-8"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.07.034"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823f3c43"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.10.053"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S96649"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S94334"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0020764015577844"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157150"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.05.004"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0269-4"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.09.007"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315612013"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1039856215576396"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S97883"},{"key":"e_1_3_2_28_1","first-page":"617","volume-title":"J Clin Psychiatry","author":"Kane JM","year":"2012","unstructured":"Kane JM, Sanchez R, Perry PP, et\u00a0al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24"},{"key":"e_1_3_2_29_1","unstructured":"European Medicines Agency. Xeplion authorization details. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002105\/human_med_001424.jsp&mid=WC0b01ac058001d125. [Last accessed 17 March 2016]"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139403"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000385"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1191945"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_3_2_35_1","unstructured":"Ijzerman MJ. Guideline for economic evaluations in healthcare. Amsterdam: Zorginstituut Nederland; June 16 2016. http:\/\/www.ispor.org\/PEguidelines\/source\/Netherlands_Guideline_for_economic_evaluations_in_healthcare.pdf. [Last accessed 10 November 2016]"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2005.07.037"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S83546"},{"key":"e_1_3_2_38_1","first-page":"A526","article-title":"Three-monthly long-acting formulation of paliperidone is a dominant treatment option, cost saving while adding QALYs, compared to the one-monthly formulation in the treatment of schizophrenia in Belgium. Poster PMH28 Presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29\u2013November 2, 2016","volume":"19","author":"De Moor R","year":"2016","unstructured":"De Moor R, Malfait B, Tedouri F, et\u00a0al. Three-monthly long-acting formulation of paliperidone is a dominant treatment option, cost saving while adding QALYs, compared to the one-monthly formulation in the treatment of schizophrenia in Belgium. Poster PMH28 Presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29\u2013November 2, 2016. Value Health 2016;19:A526","journal-title":"Value Health"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.181"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523030-00009"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01431.x"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1184156"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179049"},{"key":"e_1_3_2_44_1","volume-title":"The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care","author":"National Institute for Health and Clinical Excellence","year":"2010","unstructured":"National Institute for Health and Clinical Excellence. The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. London: NICE; 2010"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.12.002"},{"key":"e_1_3_2_46_1","unstructured":"Kim E Berwaerts J Turkoz I et\u00a0al. Time to schizophrenia relapse in relapse-prevention studies of antipsychotics developed for administration daily once monthly and every 3 months. Presented at the 15th International Congress on Schizophrenia Research Colorado Springs CO USA March 28\u2013April 1 2015"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00980.x"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651500903311821"},{"key":"e_1_3_2_50_1","unstructured":"DBC tarivien 2016 \u2013 Universitair Centrum Psychiatrie. https:\/\/www.umcg.nl\/SiteCollectionDocuments\/UMCG\/Afdelingen\/Psychiatrie\/DBC%20tarieven%202016%20-%20Universitair%20Centrum%20Psychiatrie%20%20(UCP).pdf. Accessed March 19 2016"},{"key":"e_1_3_2_51_1","unstructured":"Organisation for Economic Cooperation and Development. Consumer Price Index http:\/\/stats.oecd.org\/Index.aspx?Dataset-Code=MEI_PRICES. [Last accessed 19 March 2016]"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-35"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0348-x"},{"key":"e_1_3_2_54_1","unstructured":"Zorginstituut. https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/rapporten-en-standpunten\/2015\/1506-kosteneffectiviteit-in-de-praktijk\/Kosteneffectiviteit+in+de+praktijk.pdf. [Last accessed 16 January 2017]"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.597"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.05.052"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-013-0105-7"},{"key":"e_1_3_2_58_1","unstructured":"Plehn G Oernek A Vormbrock J et\u00a0al. [Comparison of costs and revenues in conservative and invasive treatment in cardiology: a contribution margin analysis]. Gesundheitswesen 2015;15. [Epub ahead of print] German"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147364"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2.1.29"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10729-006-9094-0"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.15171\/ijhpm.2015.53"},{"key":"e_1_3_2_63_1","doi-asserted-by":"crossref","unstructured":"Benson C Chirila C Graham J et\u00a0al. Health resource use and cost analysis of schizophrenia patients participating in a randomized multicenter double-blind relapse-prevention study of paliperidone palmitate 3-month formulation. Presented at the ISPOR 20th Annual International Meeting; Philadelphia PA May 16\u201320 2015","DOI":"10.1016\/j.jval.2015.03.699"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.699"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.10.026"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-2-8"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.838571"},{"key":"e_1_3_2_68_1","unstructured":"European Medicines Agency. Trevicta authorization details. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004066\/human_med_001829.jsp&mid=WC0b01ac0580-01d124. [Last accessed 16 November 2016]"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.1001514"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000028"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12201"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S77778"},{"key":"e_1_3_2_73_1","first-page":"420","article-title":"Comparison of primary coronary percutaneous coronary intervention between diabetic men and women with acute myocardial infarction","volume":"31","author":"Liu HL","year":"2015","unstructured":"Liu HL, Liu Y, Hao ZX, et\u00a0al. Comparison of primary coronary percutaneous coronary intervention between diabetic men and women with acute myocardial infarction. Pakistan J Med Sci 2015;31:420-5","journal-title":"Pakistan J Med Sci"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09584"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09416"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4310"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.02.003"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12294"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.02.019"},{"key":"e_1_3_2_80_1","first-page":"266","article-title":"Hospitalization rates in patients during long-term treatment with long-acting risperidone injection","volume":"5","author":"Chue P","year":"2005","unstructured":"Chue P, Llorca P-M, Duchesne I, et\u00a0al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005;5:266-74","journal-title":"J Appl Res"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500601091303"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200506"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.12927\/hcq.2011.22077"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-155"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.978"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46014"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1108"},{"key":"e_1_3_2_88_1","first-page":"263","article-title":"Remission and employment status in schizophrenia and other psychoses: one-year prospective study in Croatian patients treated with risperidone long acting injection","volume":"28","author":"Mihaljevic-Peles A","year":"2016","unstructured":"Mihaljevic-Peles A, Sagud M, Filipcic IS, et\u00a0al. Remission and employment status in schizophrenia and other psychoses: one-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatr Danub 2016;28:263-72","journal-title":"Psychiatr Danub"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903149306"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01211.x"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1067"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107084068"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S54740"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.09.006"},{"key":"e_1_3_2_95_1","unstructured":"European Medicines Agency. Risperdal Consta\u00ae summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Risperdal_Consta_30\/WC500008170.pdf. [Last accessed 2 March 2017]"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401230309085667"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2007.58.4.482"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-2-6"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.53.7.891"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12621"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00757.x"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00498.x"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0810"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-1-7"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.71272.x"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0503"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200107000-00001"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-012-0316-9"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2224"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.08.042"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X11510"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321100-00001"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80046-6"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200020030-00003"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.2147\/POR.S64973"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38881.382755.2F"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.8.1049"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/22.1.15"},{"key":"e_1_3_2_121_1","first-page":"965","volume-title":"Arch Gen Psychiatry","author":"Kane JM","year":"2001","unstructured":"Kane JM, Marder SR, Schooler NR, et\u00a0al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965-72"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371202"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.4.499"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00291-1"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1105"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199705000-00001"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.130"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199502001-00008"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.622"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.043"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.1013"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110401800306"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00486.x"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.05.002"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01026-X"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.2.255"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(00)00118-4"},{"key":"e_1_3_2_139_1","unstructured":"European Medicine Agency. Committee for Proprietary Medical Products (CPMP) summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001\/83\/EC for Leponex and associated names. November 12 2002. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Leponex_30\/WC500010966.pdf. [Last accessed November 19 2016]"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4024"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.148.2.120"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.01750310038007"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(97)00013-7"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290010048009"},{"key":"e_1_3_2_145_1","first-page":"597","volume-title":"Acta Psychiatr Scand","author":"McCreadie RG","year":"1989","unstructured":"McCreadie RG, Wiles D, Grant S, et\u00a0al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80:597-602"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.5.790"},{"key":"e_1_3_2_147_1","first-page":"S7","article-title":"Minimal effective dose and relapse\u2013double-blind trial: haloperidol decanoate vs. placebo","volume":"14","author":"Eklund K","year":"1991","unstructured":"Eklund K, Forsman A. Minimal effective dose and relapse\u2013double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol 1991;14(Suppl2):S7-S12","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_2_148_1","unstructured":"Sectorrapport GGZ. Amersfoort The Netherlands: GGZ Nederland December 2015. http:\/\/www.ggznederland.nl\/uploads\/assets\/GGZ1508-01%20Sectorrapport-2013-1.pdf. [Last accessed 10 January 2017]"},{"key":"e_1_3_2_149_1","unstructured":"ZIN Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties. Rotterdam: Erasmus University Institute for Medical Technology Assessment; 2014. https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/overige-publicaties\/1602-richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg-bijlagen\/1602-richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg-bijlagen\/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+(verdiepingsmodules).pdf. [Last accessed 19 November 2016]"},{"key":"e_1_3_2_150_1","unstructured":"NZA Tariefbeschikking gespecialiseerde geestelijke gezondheidsorg. TB\/CU-5079. Utrecht: Nederlandse Zorgautoriteit; 2016. https:\/\/www.nza.nl\/1048076\/1048144\/TB_CU_5079_01__Gespecialiseerde_geestelijke_gezondheidszorg.pdf. [Last accessed 19 November 2016]"},{"key":"e_1_3_2_151_1","unstructured":"SHL Tariffs: laboratory diagnostics. Etten-Leur The Netherlands: SHL Group. https:\/\/www.shl-groep.nl\/patient\/tarieven\/?tariefgroep=laboratoriumdiagnostiek. [Last accessed 18 November 2016]"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S41609"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2017.1363050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:09:08Z","timestamp":1770934148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2017.1363050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":151,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11,2]]}},"alternative-id":["10.1080\/13696998.2017.1363050"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2017.1363050","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}